Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

Original reporting
Published Nov 12, 2026, 11:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PHVSBearishMed
01

Why it matters

The earnings miss may trigger sell pressure, but the recent late‑stage trial win could provide upside if investors focus on future growth.

02

Market read

Micro‑cap biotech earnings with a loss; short‑term downside expected, but trial success offers a longer‑term catalyst.

03

What to watch

Potential upcoming regulatory approval timeline and cash runway may mitigate short‑term downside.

Relevance 7/10Novelty 8/10Timing: today

Background

Pharvaris N.V. (PHVS) released its Q3 2026 earnings, showing a net loss of €47.4M and EPS of -$0.67.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Q3 results disclosed EPS -$0.67 and net loss €47.4M for Pharvaris N.V.

Expected impact

likely downside as market prices in the loss

Evidence & confidence

The company reported a larger-than-expected loss, which typically triggers sell pressure in biotech microcaps.

Market effects

Biotech sector may see modest pullback as earnings disappointment spreads to peers.

European biotech investors could see slight sentiment dip.

Limited to niche biotech investors; no broad market effect.

Counterpoint

If the Phase III trial data is viewed as a long‑term catalyst, the stock could rebound despite the loss.

Key entities

  • Pharvaris N.V.

    Biotech firm developing treatments for hereditary angioedema.

Related articles

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.